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The general aim of the present thesis was to explore the optimisation of 
treatment for patients with atrial fibrillation (AF) and heart failure with either 
a preserved (HF-pEF) or reduced ejection fraction (HF-rEF). Although HF-
pEF and HF-rEF may have the same symptoms there are distinct patterns 
of structural remodeling and therefore these patients may have different 
response to therapy.(1)
 We studied a variety of patients with AF and HF-pEF or HF-rEF. In 
chapter 2 we showed that a more lenient rate control strategy is as good as 
strict rate control in patients with permanent AF and predominantly HF-pEF. 
In chapter 3 digoxin, a drug often used for rate control in patients with HF-
rEF did, in contrast to other post-hoc analyses, not deteriorate outcome in 
our RACE II patients with permanent AF. In chapter 4 we demonstrated that 
parameters associated with cardiovascular morbidity and mortality in patients 
whom recently progressed to permanent AF are a longer pre-existing history 
of AF next to higher levels of blood biomarkers high-sensitive troponin T (Hs-
Trop T) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP). 
In chapter 5 we found that in patients with AF and HF-pEF or HF-rEF the 
effect of nebivolol was attenuated as compared to those with sinus rhythm. 
When combining several AF subanalyses with beta blockers (nebivolol, 
bisoprolol, carvedilol, and metoprolol) this effect on mortality was even more 
marked. Beta-blockers were predominantly effective in patients with sinus 
rhythm and HF-rEF with respect to mortality (chapter 6). Finally, in patients 
with HF-rEF eligible for cardiac resynchronisation therapy (CRT) response 
and cardiovascular outcome in patients with AF as compared to sinus rhythm 
was comparable (chapter 7).
Mechanisms of atrial fibrillation in heart failure
At the turn of the millennium it was portrayed that AF and heart failure will 
become the two major epidemics in cardiovascular disease of the 21st century.
(2-4) This is not only related to ageing of the population, but also to changes in 
lifestyle and increased survival of patients with heart diseases. In addition, there 
is a reciprocal relationship between AF and heart failure.(3,5) Hypertension 
is the most frequently associated condition related to AF. Hypertension may 
cause diastolic heart failure. In turn, due to increased stretch and pressure 
in the left atrium HF-pEF may set the stage for AF. Also other diseases and 
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effects are avoided. The disadvantage was that the rhythm disturbance was 
than accepted. Therefore every effort was previously made in the treatment 
of AF to maintain sinus rhythm but long term success was poor.(20-22) In 
recent years several trials have shown that rate control is not inferior to 
pharmacological rhythm control with regard to cardiovascular morbidity and 
mortality.(17,18,23-25) Comparable findings have been observed for patients 
with chronic heart failure.(26,27)
 The Rhythm Control versus Rate Control for AF and Heart Failure 
(AF-CHF) trial showed in 1376 patients with AF and HF-rEF (mean left 
ventricular ejection fraction was 27%) that a rhythm strategy did not reduce 
the rate of death from cardiovascular causes, symptoms, quality of life, and 
left ventricular ejection fraction when compared to a rate control strategy.
(12,27,28) Therefore, rate control is now adopted as first choice treatment in 
patients with and without heart failure and without severe symptoms, although 
early and aggressive rhythm control could potentially show attenuated results.
(15,19,29)
 It is generally believed that a low heart rate is beneficial, both in 
patients with heart failure (11,30) and coronary artery disease.(31) However 
this may primarily be applicable to patients who are in sinus rhythm and not 
for those with AF. A major concern of a higher heart rate in patients with AF 
Figure 1. Rate or rhythm control in patients with heart failure (AF-CHF trial).(27) Reprinted with 
permission from (27).
conditions, like obesity and diabetes may cause HF-pEF and induce AF. In 
addition for the patient with HF-rEF, ischemic heart disease more often is the 
cause of AF.(6) Although HF-pEF and HF-rEF share the same phenotype 
there are distinct patterns of structural remodeling and different response to 
therapy indicating two different entities with different pathophysiology.(1,7-9) It 
is therefore essential to early identify the patient with AF in the setting of heart 
failure and to establish treatment for 1. symptom reduction and 2. optimization 
of prognosis.(10-12) Treatment should therefore be patient tailored therapy 
and focused on finding the underlying disease and symptoms of the patient.
(13) 
Rate or rhythm control for AF in heart failure
Treatment of AF in the general population focuses on control of AF related 
symptoms and prevention of stroke and heart failure.(14) When initiating 
treatment for AF, the initial assessment includes assessment of the severity 
of clinical situation and underlying diseases and conditions.(13) The severity 
of AF-related symptoms should indicate whether acute restoration of sinus 
rhythm is necessary or whether acute management of the ventricular rate is 
sufficient.(15) Thereafter, optimal treatment of the associated diseases is the 
first goal. The third step includes stroke risk assessment followed by institution 
of anticoagulants if indicated and of rate controlling drugs.(16) Only thereafter, 
one should decide whether or not a rhythm control approach should be 
adopted. Importantly, at present the only indication to abolish AF is to relieve 
patients from symptoms.(17-19).
 As mentioned in the introduction of the thesis the nomenclature rate 
versus rhythm should be considered misnomer. Many patients need rate 
control during rhythm control therapy. Therefore, rate control should be key 
therapy, also in patients who are treated with a rhythm control approach, just 
to control the ventricular rate at the very moment of recurrent AF.
 Rhythm control was long regarded as the preferred therapy for AF as 
patients could benefit from sinus rhythm by relief of symptoms. The downside 
to rhythm control was that anti-arrhythmic drugs are necessary, electrical 
cardioversion, and in recent years pulmonary vein isolation to maintain long-
term sinus rhythm. Rate control on the other hand has the advantage that 
anti-arrhythmic drug therapy is not necessary and therefore potential side-
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in the dronedarone group compared to placebo could have been related to 
redundant rate control. This conception is supported by the fact that the heart 
rate at one month in the dronedarone arm had decreased by 7.6±14.5 beats 
per minute whereas no change occurred in the placebo arm.(45) Recently, 
indeed, a a strong effect of concurrent digoxin use on the adverse effect of 
dronedarone on cardiovascular death, but not on occurrence of heart failure 
was demonstrated.(46)
 In this thesis (chapter 2) we showed in patients with permanent AF 
and predominantly HF-pEF that a lenient rate control strategy had no harmful 
effect on cardiovascular morbidity and mortality, symptoms, and quality of life.
(47) An important advantage of lenient rate control strategy was that it was 
easier to accomplish: significantly fewer additional hospital visits and lower 
number and dosages of rate control drugs were necessary to achieve the 
heart rate target. A major concern of a high heart rate has always been the 
development or deterioration of heart failure.(32,33) This was not observed in 
this analysis, and also not in a prior post-hoc analysis in patients with AF and 
moderate heart failure treated with a more lenient approach (heart rate in rest 
below 100 b.p.m).(18,26) Also in more advanced heart failure patients, a high 
heart rate was not associated with an increase in morbidity and mortality.(48) In 
agreement with these results was a subanalysis of the CHARM (Candesartan 
in Heart Failure: Assessment of Reduction in Mortality and morbidity) Program 
which observed that resting heart rate was not an important predictor of 
outcome in patients with AF and heart failure, regardless of left ventricular 
ejection fraction.(49) Apparently a more lenient rate control strategy could 
allow the physician to accomplish a heart rate low enough to prevent excess 
heart failure hospitalizations and other cardiovascular morbidity and mortality 
in patients with primarily HF-pEF.(47) 
Drugs to achieve ventricular rate control 
Ventricular rate control can be achieved by several drugs; beta-blockers, 
nondihydropyridine calcium channel antagonists, digoxin, and amiodarone 
alone or in combination. Beta-blockers are effective rate-control agents in 
both HF-rEF and HF-pEF but only reduce morbidity and mortality in HF-rEF 
patients. (37,51) Recent data suggest that nondihydropyridine calcium channel 
antagonists may be a better choice for those with HF-pEF.(39,52) These studies 
has always been the development or deterioration of heart failure.(32,33) 
However, in chapter 5 we showed that a lower heart rate by means of 
beta-blockade in patients with AF and HF-pEF or HF-rEF did not improve 
prognosis, although the overall results in the main trials with patients in sinus 
rhythm were undoubtedly positive in favor of beta-blockade therapy.(34-37) 
This effect was also observed in a meta-analysis (chapter 6), which showed 
that the cumulative effect of all beta-blockers currently indicated for HF-rEF 
was only beneficial for patients who were in sinus rhythm.(38) There was 
no beneficial effect in patients with AF, despite the fact that beta-blockade 
significantly reduced the heart rate. It is therefore suggested that titrating the 
heart rate during AF as low as during sinus rhythm with a beta-blocker is not 
necessary. Recently, it has been demonstrated that beta-blocker therapy may 
reduce exercise capacity more than calcium channel blockers in patients with 
permanent AF.(39) Nevertheless, the aforementioned beta-blocker studies 
were not performed to assess heart rate control strategies but did assess 
cardiovascular outcomes.
 Only one trial randomized patients with two different rate control 
strategies has been performed thus far: the Rate Control Efficacy in Permanent 
AF: a Comparison between Lenient versus Strict Rate Control II (RACE 
II) study.(16,40) RACE II study was a Dutch randomized multicenter study 
comparing long-term effects of lenient versus strict rate control on morbidity 
and mortality in 614 patients with permanent AF. Patients randomized to 
lenient rate control had a resting heart rate target < 110 beats per minute. 
Patients randomized to strict rate control had two heart rate targets: a resting 
heart rate target < 80 beats per minute and a heart rate target during moderate 
exercise < 110 beats per minute. After a median of 3 years of follow up no 
differences were observed between lenient and strict rate control in term of 
cardiovascular morbidity and mortality.(16) Post-hoc analyses of RACE II also 
showed no differences in atrial remodeling, quality or life or symptoms.(41-
43) Despite absence of a difference in heart failure hospitalization in RACE 
II one cannot exclude that excessive rate control (e.g. heart rates above 110 
b.p.m.) could be harmful.(33,44) In the Permanent AF Outcome Study Using 
Dronedarone on Top of Standard Therapy (PALLAS), the immediate rise in 
both co-primary composite endpoint of stroke, myocardial infarction, systemic 
embolism and death from cardiovascular causes after the start of the trial 
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fraction (chapter 2).(16,40,42,47,58,59) Potentially this is explained by a loss 
of the atrial kick and the irregularity during AF, implying that patients may need 
higher heart rates to compensate for similar cardiac output, maybe even more 
so during heart failure.(48) Finally, patients with AF less often have underlying 
ischaemic heart disease. Beta-blockers could act differently in ischaemic 
versus non-ischaemic heart failure. Also, beta-blockers may work by different 
mechanism, making a homogenous recommendation difficult.
 Of interest, although the drug is not recommended by the current 
guidelines, bucindolol another beta-blocker, was associated with improved 
cardiovascular outcome in patients with AF and HF-rEF but the numbers were 
too small to draw any definitive conclusion.(15,50,60)
Nondihydropyridine calcium channel antagonists 
The nondihydropyridine calcium channel antagonists verapamil and diltiazem 
could be used in patients with HF-pEF, but should be avoided in those with a 
HF-rEF due to negative inotropic effects.(15)
 There might be several benefits by using the nondihydropyridine 
calcium channel antagonists in the patient with AF and  HF-pEF. In several 
studies by Ulimoen et al. this is highlighted in a group of 60 patients with 
permanent AF and relatively short follow-up.(39,52,61) The RATe control in 
Atrial Fibrillation (RATAF) study was a prospective, randomized, investigator-
blinded, crossover study design to compare four drug regimens: metoprolol 
slow-release tablets 100 mg/day, diltiazem sustained-release capsules 
360 mg/day, verapamil modified-release tablets 240 mg/day, and carvedilol 
immediate-release tablets 25 mg/day. Each drug was given for a period of 
three weeks in every patient. It appeared that diltiazem was the most effective 
drug regimen for reducing the heart rate in patients with permanent AF.(52) 
Arrhythmia-related symptoms were reduced by treatment with the calcium 
channel blockers diltiazem and verapamil, but not by the beta blockers.
(52) Also several other parameters were assessed. Diltiazem or verapamil 
preserved exercise capacity and reduced levels of NT-proBNP, whereas 
treatment with metoprolol or carvedilol reduced the exercise capacity and 
increased levels of NT-proBNP.(39) Furthermore reduction of heart rate by 
the study drugs was associated with a significant reduction in levels of hs-trop 
T, which applied to all drugs.(61) 
showed that rate-reducing treatment with diltiazem or verapamil preserved 
exercise capacity and reduced levels of NT-proBNP, whereas treatment with 
metoprolol or carvedilol reduced the exercise capacity and increased levels 
of NT-proBNP.(39) Digoxin can particulary be used for ventricular rate control 
in patients with AF and HF-rEF. Especially in the patients where digoxin 
only is given to slow the ventricular rate at rest, but not during exercise.(53) 
Amiodarone is also effective in patients with AF and both HF-rEF and HF-
pEF.(27) However, because of its potential noncardiac toxicity, amiodarone is 
considered a second-line drug for rate control after a beta-blocker and digoxin 
are proven ineffective.(15) Dronedarone, effective as a rate control drug, was 
not considered safe as it increased rates cardiovascular outcomes in patients 
with permanent AF.(45)
Beta-blockers
Beta-blockers are the cornerstone treatment in patients with HF-rEF. Beta-
blockers reduce heart rate by reducing sympatholytic activity. In addition it 
has been shown effective in improving outcome in patients with sinus rhythm. 
(34-36,54-57) In the present thesis (chapter 5 and 6) we showed that beta-
blockers however, did not improve prognosis in patients with AF and HF-rEF 
or HF-pEF.(37,38) Although the mean heart rate was reduced with 10 b.p.m. 
in patients with AF this did not lead to an improved outcome. Apparently 
reducing heart rate in patients with AF should merely be done to improve 
symptoms rather than to improve outcome.(34-37)
 There could be several explanations why beta-blockers are less 
effective in patients with AF. First, the mode of action of beta-blockers is 
different during AF and sinus rhythm. During sinus rhythm, beta-blockers exert 
their heart rate-lowering effect by targeting the sinus node, whereas during 
AF their main site of action is the atrioventricular node. Secondly, it could be 
that patients with AF and heart failure benefit from a slightly higher heart rate 
as compared with patients in sinus rhythm.(51,57) In the before-mentioned 
studies, comparable heart rate reductions (mean of 10 b.p.m.) in AF patients 
with bisoprolol, carvedilol, and metoprolol, respectively, were achieved.(34-36) 
Thus, achieving low heart rates, i.e. strict rate control, may not be necessary in 
patients with AF, which is in agreement with the previously mentioned RACE II 
and the post-hoc analysis in patients with predominantly a preserved ejection 
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Why did we not observe a detrimental effect of digoxin in patients with 
permanent AF in RACE II? First, in RACE II the heart rate target was not 
achieved at all costs.(43) We did not encourage pursuing high serum 
concentrations of digoxin as compared to AFFIRM, also not in the strict rate 
control group.(16,17,43,84) In AFFIRM higher serum concentrations may 
have led to digoxin toxicity with the induction of brady- or tachyarrhythmias 
which may have contributed to the observed increased mortality.(86,87) 
Due to the narrow therapeutic index, which warrants cautious institution to 
avoid adverse effects including life threatening brady- and tachyarrhythmias.
(15,16,18,81,82,88) Second, digoxin might be the drug of choice in patients 
who were hospitalized or had worsening heart failure. This would imply that 
other factors may have influenced outcome instead of the use of digoxin.
(89) In agreement with the latter is the observation that in the Permanent AF 
Outcome Study Using Dronedarone on Top of Standard Therapy (PALLAS) it 
was suggested that in patients with a severely impaired left ventricular systolic 
function digoxin was more pro-aritmic (e.g. induction of atrioventricular block 
with an accelerated junctional rhythm).(45) Which was later confirmed in a 
subanalysis showing that patients who were on dronedarone and digoxin had 
significant higher risk on cardiovascular death.(46) There is one other limitation 
for the use of digoxin: there are interactions with many other medications, 
e.g. amiodarone and verapamil, which can lead brady- or tachyarrhythmias.
(90,91) This is pivotal to remember as the use of digoxin has an indication 
in patients with an inactive lifestyle, the elderly who often use concomitant 
medications.(15,50,90) Other important factors that can increase the risk for 
digoxin toxicity are older age, female sex, low lean body mass, and renal 
insufficiency.(90) Recently, more data came available that digoxin may be 
associated with impaired outcome in patients with AF.(92,93) In our view, the 
use of digoxin is predominantly indicated for patients with HF-rEF for long term 
rate control, and those who have an inactive lifestyle, as recommended by 
guidelines. Most importantly, however, institution should always be performed 
carefully to avoid toxicity.(15,45,50,87,90,91)
Other rate control drugs
Amiodarone is also an effective rate control drug, and it could be instituted for 
long-term treatment, but it may cause severe extracardiac events including 
thyroid dysfunction and bradycardias.(15) The role for amiodaron in patients 
Digoxin
Digoxin is one of the oldest drugs in cardiovascular medicine.(62) Discovered 
more than 200 years ago and already in those days frequently used to relieve 
patients with dyspnea and palpitations.(62) According to current AF and heart 
failure guidelines digoxin is only indicated for long-term rate control in patients 
with AF and HF-rEF or patients who have an inactive lifestyle (e.g. elderly).
(15,63) There are several reasons why the use of digoxin has declined, most 
importantly there is no evidence that digoxin is an effective rate control drug 
during exercise, but only during rest.(53,64-77) The effect of digoxin seems 
to be most pronounced when combined with a beta-blocker. The latter 
combination has been observed to improve symptoms and left ventricular 
ejection fraction.(64,67,72,77) However, with beta-blocker mono-therapy it 
may also possible to achieve an adequate heart rate in many patients (see 
table 1).(15,63) This suggests that in general no recommendations can be 
given. Rate control should be instituted individually depending on symptoms.
Digoxin is an old drug. Nevertheless, in patients with AF no large randomized 
trials have been performed thus far. The only randomized trial with digoxin, 
which only included patients with sinus rhythm, was the Digitalis Investigation 
group (DIG) trial which investigated the effect of digoxin as compared to 
placebo on mortality in patients with HF-rEF and sinus rhythm.(78) Digoxin 
was not able to demonstrate mortality benefit but did reduce heart failure 
hospitalizations.(78) Even more important, several post-hoc analyses of the 
DIG trial reported on side-effects of digoxin.(79-81) Especially patients who 
had high serum concentrations of digoxin were at risk for mortality.(82)
 Data on cardiovascular ouctomes from patients with AF who used 
digoxin are predominantly derived from post-hoc analyses from the AF 
Follow-up Investigation of Rhythm Management (AFFIRM) trial.(17) A study 
reporting on predictors for mortality in the AFFIRM trial reported that digoxin 
was independently associated with increased mortality in patients with AF.(83) 
More recently two additional post-hoc analyses of AFFIRM on the effect of 
digoxin were conducted and reported conflicting results of its effect on 
prognosis.(84,85) In this thesis (chapter 3) we performed an analyses which 
showed that in patients with permanent AF digoxin use was not associated 
with an impaired outcome. Also we did not observe an increase in arrhythmic 
events in those using digoxin.
136
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appropriate treatment of AF. Currently, this is investigated in the Clinical effect 
of heart failure management via home monitoring with a focus on AF (EffecT, 
NCT00811382).
What to ablate?
Atrial ablation including pulmonary vein isolation is a rhythm control option in 
patients with AF with HF-pEF or HF-rEF.(112,113) Early rhythm control could 
limit structural remodeling and therefore also progression of AF into a more 
permanent state, also in patients with heart failure.(19,114) A recent meta-
analysis underlines this view. When pulmonary vein isolation is performed 
early after start of AF and heart failure it may improve left ventricular 
systolic function.(115) Furthermore, this may potentially reduce AF related 
complications.(19,114) The percutaneous technique includes pulmonary 
vein isolation. Most likely, due to extensive disease (this depends upon the 
type of AF and also degree of left atrial disease) additional ablation lines, 
such as linear ablation and/or focal ablations of areas with evidence of scar, 
fractionation, or rotor-perpetuation, may be necessary. (116-119) Pulmonary 
vein isolation has been shown effective especially in patients with paroxysmal 
AF. This procedure, however, is less successful in patients with persistent AF 
and in AF patients with heart failure concommitantly.(120-122,122-126)
 In the Comparison of Pulmonary Vein Isolation Versus AV Nodal 
Ablation With Biventricular Pacing for Patients With AF With Congestive Heart 
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with heart failure is primarily reserved for those unable to tolerate a beta-
blocker or digoxin.(50)
Non-pharmacological treatment for patients with atrial 
fibrillation and heart failure
Cardiac resynchronization therapy 
CRT is an important non-pharmacological therapeutic strategy in patients with 
heart failure.(50,94) Although AF is common in patients with heart failure large 
CRT trials have always excluded patients with prevalent AF, with the exception 
of one.(95-98) Data from patients with AF is therefore mainly derived from 
retrospective analyses. These studies show that outcome is worse for AF 
patients.(99-104) The reason for that is that AF limits biventricular pacing due 
to its fast intrinsic ventricular response. Retrospective analyses have shown 
that outcome is more beneficial when biventricular pacing is more than 98%.
(103) Several options are available to increase this percentage of biventricular 
pacing in patients with AF. The most effective one and also recommended 
by the guidelines is atrioventricular node ablation.(101,102,104-107) It 
remains uncertain whether this procedure, which has a substantial chance of 
complications and which makes patients completely pacemaker dependent, 
is absolutely necessary. No randomized clinical trials confirming the beneficial 
effect of atrioventricular junctional ablation versus optimal strict rate control 
have been performed.(101,102,104-109) In chapter 7 we showed the results 
of CRT in consecutive patients with HF-rEF and AF compared to those with 
sinus rhythm treated in the University Medical Center Groningen in the 
Netherlands. Our data suggest that response can equally be obtained in those 
with AF as compared to those with sinus rhythm when rate control is carefully 
instituted and carefully monitored including an exercise test to document 
biventricular pacing during exercise.
 Our data also show that new-onset AF itself was not associated with 
lower response or long-term heart failure hospitalizations or cardiovascular 
mortality, in contrast to earlier reports.(99,110) Interestingly, the development 
of new-onset AF occurring shortly after CRT implantation was, however, 
associated with unfavorable outcome, as has been demonstrated before.
(99,110) Therefore, it seems reasonable to monitor AF carefully after 
implantation to ensure adequate therapy for AF and biventricular pacing.
(15,111) Home monitoring may become a way to ensure early detection and 
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itself. This may relate to prolonged time in AF suggesting more progression of 
the associated diseases.(151,152) Other important determinants for prognosis 
in the RACE II study were biomarkers for heart failure and cardiac damage, 
namely NT-proBNP and hs-Trop T. (153-159)
 In RACE II we observed two important things associated with NT-
proBNP. First, in this population with permanent AF without severe heart 
failure NT-proBNP was elevated (Figure 4). Second, in agreement with 
other studies, it was associated with cardiovascular outcome. The increased 
plasmalevel of NT-proBNP may be related to concealed heart failure, being 
Figure 3. Incidence of the primary outcome stratified by biomarkers levels and duration of atrial 
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Failure (PABA-CHF) trial 41 AF and HF patients underwent pulmonary-vein 
isolation, and 40 underwent atrioventricular-node ablation with biventricular 
pacing. These were followed for 6 months. The composite primary end point 
favored the group that underwent pulmonary-vein isolation, with an improved 
questionnaire score at 6 months, a longer 6-minute-walk distance and a 
higher ejection fraction. This indicates that pulmonary-vein isolation (non-
pharmacological rhythm control) was superior to atrioventricular-node ablation 
with biventricular pacing (non-pharmacological rate control) in patients 
with heart failure who had drug-refractory AF (figure 2).(120) However, as 
indicated before, success of pulmonary vein isolation is lower in patients with 
heart failure.
 As ablation of the atrioventricular node is a definitive procedure 
making patients pacemaker dependent the rest of their life, and complications 
can occur, it may be therefore be reasonable, although definitive success is 
low, to perform pulmonary vein isolation first in these patients depending on 
parameters associated with success, e.g. left atrial size.(120,123,124,126) 
Prognosis, cardiovascular outcomes, AF progression and 
biomarkers
Whether or not AF actually influences prognosis in patients with heart failure 
remains a matter of debate.(4,11,100,127-135) This applies for both patients 
with HF-rEF and HF-pEF.(130,136,137) Recent data suggest that one of 
the factors associated with an impaired prognosis of AF is progression from 
selfterminating AF to more permanent nonselfterminating forms of AF.(138-
145,145) Progression of AF to a more permanent state occurs in 4-15% of 
the patients during the first year. Parameters associated with AF progression 
include clinical parameters like age, congestive heart failure, history of 
hypertension or diabetes mellitus,(139,146) next to modifiable risk factors like 
sleep apnea syndrome and obesity. Adjustment of these factors may prevent 
AF progression.(147-150) Data on risk factors for cardiovascular morbidity 
and mortality in patients who recently progressed to permanent AF is sparse. 
In chapter 4 we showed that duration of AF prior to study enrollment is one of 
the key determinants for prognosis in patients who who recently progressed 
to non-selfterminating permanent AF. Hypothetically, the total history duration 
of AF (figure 3) seems more indicative for prognosis than classification of AF 
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to assess the actual risk. Potentially, blood biomarkers assessing different 
cardiac and vascular remodeling processes  involved in AF (Figure 6) may 
contribute to assess the actual risk in the individual patients. 
 In this respect, also biomarkers associated with a prothrombotic state 
(e.g. d-dimer) may help to assess the risk on and etiology of stroke in the 
individual patient as was recently demonstrated.(166) Whether or not these 
biomarkers will be able to assess prognosis or are helpful in risk classification 
likewise to NT-proBNP and hs-trop T has yet to be investigated.(157,159,167-
176)
Future perspectives 
As part of the conclusions of this thesis are based on subanalyses and non-
randomized comparisons this should serve hypothesis generating for future 
trials. The discussion whether sinus rhythm could improve outcome as 
compared with rate control is once more being challenged as atrial ablation 
is becoming more effective, also in patients with more severe underlying 
disease.(112,113,177,178) Whether or not pulmonary vein isolation will be 
superior to anti-arrhythmic drug therapy or adequate background rate control 
therapy is now being investigated in several large randomized trials; Catheter 
ablation versus anti-arrhythmic drugs therapy for AF trial (CABANA, Clinical 
Trials.gov Identifier NCT00911508), in the Early treatment of AF for stroke 
prevention trial (EAST, ClinicalTrials.gov Identifier NCT01288352),(19) and 
also in heart failure patients in the Catheter Ablation With or Without Anti-
arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With 
Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker 
Treatment for AF (RAFT-AF, Clinical Trials.gov Identifier NCT01420393), and 
Catheter Ablation vs. Standard Conventional Treatment in Patients With Left 
Ventricular Dysfunction and AF (CASTLE-AF, Clinical Trials.gov Identifier 
NCT00643188). Also early identification of patients with AF and heart failure 
could lead to an improved outcome as early identification and therapy of high-
risk patients may improve outcome. Better risk identification may in addition 
help to develop novel therapies for specific patients. We could, for example 
start early and aggressively with ‘upstream’ therapy in high-risk patients to 
reverse the remodeling process at an early stage, in combination with lifestyle 
changes (exercise and nutrients).(179,180) Results of the upstream therapy 
secreted in the ventricles. Alternatively, or in combination, it may be secreted 
in the atria due to atrial stretch (figure 4).(160-164) 
 In this thesis (chapter 4, figure 5) we found that hs-Trop T was an 
independent predictor for several cardiovascular outcomes in RACE II, which 
is in accordance other recent studies showed.(157,165) Interestingly, as well 
in RE-LY as in RACE II tropinin identified higher risk patients with low CHADS2 
scores.(165) 
 The other way around, patients with high CHADS2 but with a low level 
of hs-Trop T showed a lower risk on stroke, despite having a high CHADS2 
score. This shows that the presently used clinical risk scores are not optimal 
Figure 5. The occurrence of stroke and systemic embolism by hs-Trop T and CHADS score in 


































CHADS2: 3 or more CHADS2: 2 CHADS2 0 or 1
Figure 6. Biomarkers linked to AF. 
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